Completed
Intro
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Kidney Cancer Clinical Updates and Research Highlights from 2023
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Results from phase 3 study of Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON)
- 3 ZIRCON: Summary
- 4 Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (1) in first-line advanced RCC (ARCC) of IMDC intermediate or poor risk.
- 5 Baseline characteristics by IMDC risk
- 6 PFS by IMDC risk group
- 7 Tumor response by IMDC risk
- 8 Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3- year follow-up from the phase 3 CheckMate 9ER trial.
- 9 Best overall response by IMDC risk
- 10 Time to subsequent therapy for patients completing 2 years of nivolumab
- 11 CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC)
- 12 CaboPoint: Patient characteristics
- 13 Interim efficacy analysis
- 14 Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
- 15 Survival states, favorable risk
- 16 Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (10)-based regimens
